ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 479,40
-0,68%
Dow Jones
39 118,86
-0,12%
DAX
18 235,45
0,17%
Brent Oil
85,17
0,38%
Bitcoin
62 794,81
3,13%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Nexalin Technologies Inc (NXLIW)

  7. Nexalin Technologies Inc (NXLIW) Actualités

NXLIW

Nexalin Technologies (NXLIW)

Nexalin Technologies Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:NXLIW
DateHeureSourceTitreSymboleSociété
28/06/202403h15GlobeNewswire Inc.Nexalin Technology Announces Pricing of $5.2 Million Public OfferingNASDAQ:NXLIWNexalin Technologies Inc
26/06/202415h00GlobeNewswire Inc.Nexalin Technology Announces Positive Clinical Study Data in Major Depressive Disorder and Publication of Clinical Trial Results in Leading Scientific JournalNASDAQ:NXLIWNexalin Technologies Inc
20/06/202414h30GlobeNewswire Inc.Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer’s and DementiaNASDAQ:NXLIWNexalin Technologies Inc
18/06/202423h02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NXLIWNexalin Technologies Inc
14/06/202415h53Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:NXLIWNexalin Technologies Inc
13/06/202421h00GlobeNewswire Inc.Nexalin Technology Announces Regulatory Approval to Sell Nexalin’s Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)NASDAQ:NXLIWNexalin Technologies Inc
12/06/202419h19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NXLIWNexalin Technologies Inc
04/06/202414h30GlobeNewswire Inc.Nexalin Technology to Present at the Spring MicroCap Rodeo Conference on June 6thNASDAQ:NXLIWNexalin Technologies Inc
03/06/202414h30GlobeNewswire Inc.FDA Provides Feedback and Reaches Consensus on Nexalin’s Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity™ Headset DeviceNASDAQ:NXLIWNexalin Technologies Inc
23/05/202423h17Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:NXLIWNexalin Technologies Inc
22/05/202414h30GlobeNewswire Inc.Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research EffortsNASDAQ:NXLIWNexalin Technologies Inc
14/05/202422h54Edgar (US Regulatory)Form RW - Registration Withdrawal RequestNASDAQ:NXLIWNexalin Technologies Inc
10/05/202420h50Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NXLIWNexalin Technologies Inc
09/05/202414h30GlobeNewswire Inc.Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on May 23NASDAQ:NXLIWNexalin Technologies Inc
25/04/202416h44GlobeNewswire Inc.Nexalin Technology Regains Compliance with Nasdaq Continued Listing RequirementsNASDAQ:NXLIWNexalin Technologies Inc
09/04/202414h30GlobeNewswire Inc.Nexalin Technology Accelerates Manufacturing of its HALO™ Clarity Following Successful Usability, Feasibility, and Electrical TestingNASDAQ:NXLIWNexalin Technologies Inc
04/04/202419h00GlobeNewswire Inc.Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation DeviceNASDAQ:NXLIWNexalin Technologies Inc
02/04/202414h30GlobeNewswire Inc.Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory BoardNASDAQ:NXLIWNexalin Technologies Inc
28/03/202413h30GlobeNewswire Inc.Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San DiegoNASDAQ:NXLIWNexalin Technologies Inc
14/03/202413h30GlobeNewswire Inc.Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin’s TechnologyNASDAQ:NXLIWNexalin Technologies Inc
13/03/202413h30GlobeNewswire Inc.Nexalin Technology Announces Poster Presentation at “State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment”NASDAQ:NXLIWNexalin Technologies Inc
08/02/202414h30GlobeNewswire Inc.Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation DeviceNASDAQ:NXLIWNexalin Technologies Inc
23/01/202414h30GlobeNewswire Inc.Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device – the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) SystemNASDAQ:NXLIWNexalin Technologies Inc
11/01/202414h30GlobeNewswire Inc.Nexalin Technology Unveils Next-Generation HALO™ ClarityNASDAQ:NXLIWNexalin Technologies Inc
18/12/202314h30GlobeNewswire Inc.Nexalin Technology Reports Significant Positive Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device on Treatment-Resistant DepressionNASDAQ:NXLIWNexalin Technologies Inc
25/10/202314h30GlobeNewswire Inc.Nexalin Technology Announces Formation of New Military & Government Advisory Board to be Led by Government Affairs Veteran David LasseterNASDAQ:NXLIWNexalin Technologies Inc
16/10/202314h30GlobeNewswire Inc.Nexalin Technology Announces Publication of Groundbreaking Deep-Brain Stimulation Study in Leading Peer-Reviewed Journal; Validates the Ability of Nexalin’s Neurostimulation Device to Penetrate Deep Brain StructuresNASDAQ:NXLIWNexalin Technologies Inc
07/08/202314h30GlobeNewswire Inc.Nexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device in Treating Migraine Headaches and Related SymptomsNASDAQ:NXLIWNexalin Technologies Inc
03/08/202314h30GlobeNewswire Inc.Nexalin’s CEO Mark White to be Interviewed Live on “The Big Biz Show” Today at 3PM Eastern TimeNASDAQ:NXLIWNexalin Technologies Inc
26/07/202314h30GlobeNewswire Inc.Nexalin Technology Announces New Public Sector Division to Capitalize on Opportunities to Serve U.S. Government AgenciesNASDAQ:NXLIWNexalin Technologies Inc
 Showing the most relevant articles for your search:NASDAQ:NXLIW

Dernières Valeurs Consultées

EU
ORA
Orange
EU
ACA
Credit Agricole
EU
AF
Air FranceKLM
EU
BN
Danone
EU
BNP
BNP Paribas
NASDAQ
NVDA
NVIDIA
NASDAQ
GOOGL
Alphabet
EU
VIV
Vivendi
NYSE
DIS
Walt Disney
EU
RI
Pernod Ricard
EU
LR
Legrand
NYSE
MRK
Merck
EU
SGO
Cie de SaintGobain
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés